Aranesp "Functional Equivalence" Status Not Subject To Judicial Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal appeals court says the Medicare agency did not exceed its statutory authority in determining that Amgen’s anemia agent should be reimbursed at the same rate as J&J’s Procrit.